Table 1. Comparison of patient demographics, ACR TIRADS categories and CAD values according to the BRAFV600E mutation status.
| BRAF + (n = 380) | BRAF- (n = 89) | P-value | |
|---|---|---|---|
| Age (years) | 43.1 ± 12.9 | 38.9 ± 11.8 | .005 |
| Sex | .588 | ||
| Female | 288 (75.2) | 65 (88.6) | |
| Male | 92 (24.8) | 24 (11.4) | |
| Tumor size (mm) | 16 ± 7.3 | 20.8 ± 10.6 | < .001 |
| ACR TIRADS* | < .001 | ||
| 2 | 1 (0.3) | 4 (4.5) | |
| 3 | 6 (1.6) | 11 (12.4) | |
| 4 | 65 (17.1) | 12 (13.4) | |
| 5 | 308 (81) | 62 (69.7) | |
| CAD value | 77.9 ± 21.8 | 60.9 ± 31.6 | < .001 |
*Fisher’s exact test
Note—Age, tumor size, and CAD value are shown as means and standard deviations.
Categorical variables are shown as numbers of patients with percentages in parentheses.
BRAF+ = BRAFV600E mutation-positive, BRAF- = BRAFV600E mutation-negative
ACR TIRADS = the American College of Radiology Thyroid Imaging, Reporting and Data System
CAD value = risk of malignancy from CAD